Definitive Contract DAMD1798C8024
Award Date
11/6/97
Potential Completion Date
7/23/23
Potential Value
$1.2B
Funding Federal Agency
Medical Command
Contracting Federal Agency
Defense Contract Management Agency
Awardee
Dynport Vaccine Company LLC
Ultimate Awardee
General Dynamics Corp
NAICS Category
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Award Fee
Place of Performance
Fort Detrick, MD 21702, USA
Solicitation Procedures
Sealed Bid
Number Of Offers Received
4
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a cost-plus-fixed-fee delivery order awarded by the Medical Command (MEDCOM) of the U.S. Army to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation. The $1,685,156.08 contract is for the Phase 2 clinical trial of the Comprehensive Preventive and Preparedness (CPP) program, which develops medical countermeasures for infectious diseases. The contract is part of Dynport's existing $30 million Preclinical Services for Biopharmaceutical Product Development indefinite...
This is a cost-plus-fixed-fee definitive contract awarded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $258,064,432.13 contract is for program reporting and technical services in support of the development and delivery of an FDA-licensed human plasma-derived butyrylcholinesterase (HuBChE) product. The award does not have a set-aside designation. Dynport Vaccine Company...
This is a $3,860,186.71 cost-plus-fixed-fee task order awarded to Dynport Vaccine Company LLC (DVC), a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The task order is for Phase 1 clinical trials of therapeutics against infectious diseases and was issued under the Therapeutics Against Infectious Diseases Phase 1 indefinite-delivery, indefinite-quantity...
This is a delivery order awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. The $129,670.00 award is part of the Therapeutics Against Infectious Diseases Phase 1 contract vehicle, a multi-year indefinite delivery, indefinite quantity (IDIQ) contract that funds early-stage clinical trials of candidate therapeutics and vaccines. The...
This is a Cost Plus Fixed Fee delivery order contract awarded by the Defense Health Agency to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp, to perform research and development in support of the U.S. Army Medical Materiel Development Activity (USAMMDA). The contract is for a Phase I, multi-center, randomized, double-blind, placebo-controlled study to assess the long-term ophthalmic safety of tafenoquine versus placebo. The potential value of the contract is $24,238,920.68,...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.2 million delivery order contract to Dynport Vaccine Company LLC DVC Segment Division for the evaluation of cell lines producing a monoclonal antibody, and production and characterization of a cGMP master cell bank. Dynport Vaccine Company LLC DVC Segment Division, a subsidiary of General Dynamics Corp., will perform this work under its Preclinical Services...
This is a $2,265,501.00 delivery order contract awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Early Phase Clinical Trial Units (EPCTU) IDIQ contract vehicle. The contract is for cost plus fixed fee services to support early phase clinical trials, with a period of performance through July 15, 2025. The contract does not have a set-aside designation. Dynport Vaccine Company has...
This is a delivery order award to Dynport Vaccine Company LLC (DVC), a subsidiary of General Dynamics Corp, under the $36 million Diagnostic Pre-Clinical Services Program IDIQ contract with the National Institute of Allergy and Infectious Diseases (NIAID). The task order is for a 7-year period of performance with a ceiling value of $3,500. It does not have a set-aside designation. Under this contract, DVC will provide a range of research, development, manufacturing, and testing services to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,500 firm fixed price delivery order contract to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for the Diagnostic Pre-Clinical Services Program. This contract is part of a larger Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle that provides funding for development processes needed to bring candidate infectious disease diagnostics to market. Dynport has previous experience...
This federal contract award is for FY21 BMFRP SUPPORT SERVICES, a delivery order issued by the Medical Command of the U.S. Department of Defense to General Dynamics Information Technology, Inc. (GDIT), a subsidiary of General Dynamics Corporation. The $80,007.48 cost-plus-fixed-fee contract, which does not have a set-aside designation, supports services at Fort Detrick, Maryland. As a prominent IT and engineering services provider to various federal agencies, GDIT's work under this contract...